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Abstract
Background: Glioblastoma is the most common and deadly primary brain tumor in adults. Low-dose,metronomic
(LDM) temozolomide (TMZ) displays improved efficacy in the treatment of glioblastoma by targeting angiogenesis,
but has a limited effect on recurrence. The antiangiogenesis drug ginsenoside Rg3 (RG3) is the main active
ingredient of ginseng, a popular herbal medicine.
Methods: Using an in vitro and a rat model of an orthotopic glioma allograft, this study was to determine whether
RG3 enhanced the antiangiogenesis activity of LDM TMZ in the treatment of glioblastoma.
Results: Our results showed that combined use of TMZ with RG3 displayed additive inhibition on proliferation of
both human umbilical vein endothelial cells (HUVEC) and rat C6 glioma cells in vitro. They additively arrested cell
cycle, increased apoptosis, and decreased VEGF-A and BCL-2 expression in HUVEC. Antiangiogenesis effect was also
evaluated in the rat model of orthotopic glioma allograft, based upon markers including relative cerebral blood
volume (rCBV) by magnetic resonance imaging (MRI), VEGF levels and microvessel density (MVD)/CD34 staining.
LDM TMZ alone was potent in suppressing angiogenesis and tumor growth, whereas RG3 alone only had modest
antiangiogenesis effects. Combined treatment significantly and additively suppressed angiogenesis, without additive
inhibitory effects on allografted tumor growth.
Conclusions: These data provide evidence showing the efficacy of LDM TMZ on glioma treatment. The combined
additive antiangiogenesis effect suggests that RG3 has the potential to further increase the efficacy of LDM TMZ in
the treatment of glioblastoma.
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Background
Glioblastoma is the most common and lethal primary
brain cancer in adults. The current standard treatment
for this newly diagnosed disease is initial maximal feas-
ible surgery with subsequent radiation plus chemother-
apy [1, 2]. Temozolomide (TMZ) is the second
generation of alkylating agents with excellent oral bio-
availability and good penetration across the blood brain
barrier [3, 4]. TMZ combined with radiotherapy im-
proves glioblastoma patient survival rates and prolongs
the progression-free survival compared with radiation
therapy alone [1]. It is currently the preferred first line
chemotherapeutic drug in combination with radiation in
the treatment for glioblastoma. However, the five-year
survival rate after the diagnosis is still less than 8 %
under current standard therapy [5–7].
Glioblastoma is a highly vascularized tumor, rarely
having extracranial metastases. As high as 40–50 % of
glioblastoma’s have high levels of VEGF, the strongest
proangiogenic factor in the induction of tumor angio-
genesis. High VEGF correlates with a poor overall clin-
ical prognosis. Glioblastoma is therefore an ideal disease
for antiangiogenesis treatment [8].
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The low-dose metronomic (LDM) chemotherapy is
given by continuously administering a drug at a rela-
tively low dose, with minimal intervals. LDM use of
traditional drugs in cancer therapy was initially con-
ducted in animal models with neuroblastoma [9] and
Lewis lung cancer [10]. LDM use of the chemotherapeu-
tic drug vinblastine significantly reduced the size of
xenografted neuroblastoma’s and inhibited tumor angio-
genesis. Metronomic vinblastine in combination with
the VEGF receptor-2 antibody (DC101) led to complete
regression of the established neuroblastoma and no re-
lapse in over a 6 month period, with little toxicity [9]. In
another study, the LDM use of cyclophosphamide was
three fold more effective in reducing both xenografted
Lewis lung carcinoma and EMT-6 breast cancer in nude
mice, compared with the conventional regimen [10].
Low dose metronomic (LDM) use of the traditional che-
motherapeutic drugs have been shown to target both
proliferating tumor cells and endothelial cells, and
minimize toxicity [11, 12].
The LDM TMZ demonstrated an antiangiogenic effect
in an orthotopic glioma model [13]. Brock et al. demon-
strated that a continuous daily administration of TMZ at
a dose of 75 mg/m2/day for periods up to 6–7 weeks can
be well tolerated without a significant increase in toxicity
[14]. LDM TMZ has been shown to prolong glioblast-
oma patient progression-free interval survival, with less
toxicity [15–17]. A recent meta-analysis shows that
LDM TMZ improves the overall clinical benefit rate,
and lengthens progression-free survival; however, no
overall survival is observed between metronomic and
standard regimen [17]. Therefore, it is of exceptional
clinical significance to identify antiangiogenetic drugs
which can further improve the efficacy of LDM TMZ to
extend glioblastoma patients’ survival [18].
Ginseng is a popular herbal medicine in Asian coun-
tries used to improve health and treat certain chronic
diseases [19]. Many studies have reported that ginseng
promotes a wide range of pharmacologic activities in the
immune, cardiovascular, endocrine, and central nervous
systems. In recent years, ginseng has begun to gain sig-
nificant popularity in Western societies. As the main
active ingredient of ginseng, ginsenoside Rg3 (RG3) is
the protopanaxadiol type of dammarane ginsenoside
consisting of characteristic genuine aglycone moieties
[20]. RG3 has multiple functions in immune regulation,
anti-oxidation, anti-inflammation, anti-aging and anti-
fatigue. Its antiangiogenesis along with anti-tumorigenic
effects have been shown in several cancers [21–23].
More strikingly, RG3 has a synergistic effect with several
chemotherapy drugs to reverse multi-drug resistance of
tumor cells [24–26]. Its tumor suppressor effect was also
observed in glioma in vitro [27, 28]. The objective of this
study was to determine whether RG3 in combination
with LDM TMZ is capable of enhancing antiangiogen-
esis activity.
Methods
Cell lines and reagents
Primary human umbilical vein endothelial cells
(HUVECs) were obtained from ScienceCell (Beijing,
China). HUVECs were maintained in endothelial cell
medium (ECM) supplemented with 10 % fetal bovine
serum, 4 ng/ml FGF4, 2 ng/ml VEGF165, 100 unit/ml
penicillin and 100 μg/ml streptomycin. Rat C6 glioma
cell line was purchased from Shanghai Institutes for Bio-
logical Sciences (Shanghai, China). Rat C6 glioma cells
were maintained in RPMI 1640 medium supplemented
with 10 % newborn calf serum, 100 unit/ml penicillin
and 100 μg/ml streptomycin at 37 °C in a 5 % CO2 incu-
bator. CellTiter 96® Queous Non-Radioactive Cell Prolif-
eration Kit (MTS) was provided by Promega (Madison,
WI). Both VEGF and CD34 antibodies were purchased
from ABCAM (Hangzhou, China). The horseradish per-
oxidase conjugated goat anti-rabbit IgG second antibody
(H + L) was purchased from MultiSciences Biotech Co.,
Ltd (Hangzhou, China). Primers for GAPDH, Bcl-2 and
VEGF were synthesized by Invitrogen (Grand Island,
NY). The primer sequences and the expected sizes were:
GAPDH primer forward, CAA CTC CCT CAA GAT
TGT CAG CAA and reverse, GGC ATG GAC TGT
GGT CAT GA, 118 bp; Bcl-2 primer forward, CCA
GCG TAT ATC GGA ATG TGG and reverse, CCA
TGT GAT ACC TGC TGA GAA G, 116 bp; VEGF pri-
mer forward, TTA CGG TCT GTG TCC AGT GTA and
reverse, TTC TCT GTT ATG TTG CCA GCC, 108 bp.
Cell proliferation assay
HUVEC and C6 glioma cells (2 × 104) were first incu-
bated in 24-well plates for 24 h. Cells were then treated
with 0–180 μg/ml of TMZ and/or 0–180 μg/ml of RG3
for up to 144 h. The same fresh media was replaced
every three days. At the end of treatment, 80 μl MTS
mix was added into 400 μl of culture media and incubated
for 3 h. Optical density (OD) at 592 nm was obtained by
Infinite M200 spectrometry (Tecan Inc. Sweden). Cell in-
hibition rate was calculated as 100 % - (OD of treatment
group – OD of background wells) / (OD of control group
-OD of background wells) × 100 %. The experiments were
performed in triplicates and repeated at least twice. The
MTS assay results were validated by cell counting, using
hemocytometer after trypan blue staining.
Cell apoptosis assay
HUVEC and C6 glioma cells (2 × 104) were first seeded
in 24-well plates for 24 h. Cells were then treated with
0–180 μg/ml of TMZ and/or 0–180 μg/ml of RG3 for
up to 72 h. Treated cells were stained with DAPI. DNA
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content of DAPI stained cells was analyzed by DNA
fluorescent photometer (Nikon P100, Nikon, Tokyo,
Japan). Based on DNA content and morphological char-
acteristics, these cells then were classified into three
groups: normal cells, apoptotic cells and necrotic cells.
A total of 1000 cells of each sample were randomly se-
lected and analyzed. The apoptotic rates were calculated
by number of apoptotic cells per total number of cells ×
100 %. The experiment was conducted in triplicates and
repeated three times.
Cell cycle assay by flow cytometry (FCM)
Treated cells were fixed in 70 % ethanol and stored
at −20 °C. For FCM assay, frozen cell were first
washed with PBS and then incubated with propidium
iodide (1 mg/ml) at 4 °C for 30 min. Processed cells
were analyzed using FACSCanto flow cytometer (BD
Biosciences, San Jose, CA) and results were assessed
by the Lysis software (BD Biosciences).
DNA ladder assay
After washing with PBS, treated cells were lysed with
the buffer (1 mg/ml proteinase K in 10 mM Tris–
HCl, pH 8.0, 150 mM NaCl, 10 mM EDTA and 0.4 %
SDS). Cell DNA was then extracted with phenol and
chloroform method and resuspended in TE buffer
(10 mM Tris HCl, pH 7.5 and 0.2 mM EDTA). The
DNA samples were then separated on 2.0 % agarose
gel and visualized.
Real-time PCR
RNA was extracted by RNeasy kit (Qiagen, Shanghai,
China) following the manufacturer’s protocol. Real time
PCR was performed with SYRB PrimeScript RT-PCR
Kit (Takara, Japan) at 95 °C 15 s, 60 °C 1 min and 72 °C
for 1 min for 40 cycles. The melting curve was pro-
duced to validate the amplification of one target gene.
GAPDH was used as the internal reference for the
normalization of RNA quantity. VEGF and Bcl-2
mRNA levels in HUVEC were obtained based on
threshold cycle (CT) using the formula: the amount of
target gene expression =2-ΔΔCt, ΔΔCt = Ct of target
gene - CT of GAPDH.
Tumor implantation and treatment
Animal care was handled and maintained in accord-
ance to the established protocols from the Experi-
mental Animal Center of Zhejiang University of
Traditional Chinese Medicine. A total of 34 adult
male Wistar rats (250 to 300 g) were used for the
allograft study. The implantation surgery was per-
formed using the classical published stereotactic
protocol [29]. Under general anesthesia with 1 %
pentobarbital sodium (i.p.), the rat was placed in a
stereotactic frame and fixed with two ear bars. Skin
and periosteum were incised and a burr hole was
drilled at the coordinates for the right caudate nu-
cleus (1 mm anterior and 3 mm lateral to bregma).
Rat C6 glioma cells (5 × 106 in 10 μl serum free
media with 1 % agarose) were injected into the caud-
ate nucleus area using a Hamilton microsyringe.
After inoculation for 13 days, 31 out of 34 rats devel-
oped tumors based on MRI scanning. These tumor bear-
ing rats were then randomly assigned to five treatment
groups (n = 6 each, except for the control group n = 7).
Rats in the maximum tolerated dose of TMZ (MTD
TMZ) group were orally administered with 30 mg/kg
daily for 3 days. Rats in the low-dose metronomic TMZ
(LDM TMZ) group were orally treated with 5 mg/kg/
day for eight continuous days. RG3 at 10 mg/kg/day was
administrated orally for 8 days to rats in the RG3 group.
Rats in the LDM TMZ combined with RG3 group were
fed daily with both TMZ (5 mg/kg) and RG3 (10 mg/kg)
for 8 continuous days. Rats in the control group were
administrated with PBS only. The rat’s weights were
checked at twice a week. The tumors were scanned by
magnetic resonance imaging (MRI) at the day 13 and 23
after tumor cell injection. All rats were then terminated
after the second MRI scanning.
Magnetic resonance imaging
All rats were subjected to MRI scanning at days 13 and
23 after inoculation of the rat C6 glioma cells. Rats were
anesthetized during imaging with 1–1.5 % inhaled iso-
flurane and monitored during imaging with respiratory
monitoring. Images were captured using the Simens3.0 T
MRI scanner following a similar procedure described
previously [30]. A single-dose pre-load method was ap-
plied for perfusion imaging [30]. The contrast agent
gadobenate dimeglumine was injected at 0.2 mmol/kg,
and repeated with the same dose after 5 min. All the
images were transferred to the post-processing work-
station for image analysis. Relative cerebral blood vol-
ume (rCBV) of each selected layer was calculated
based on the pixel analysis and the maximum tumor
CBV areas (avoiding normal blood vessels and necro-
sis areas) were selected.
Tumor necrosis areas were analyzed on T1 + C MRI
images using the scanner software. Percentage of necro-
sis area was calculated by the formula: necrosis area ÷
the tumor section area × 100.
Immunohistochemical (IHC) staining
IHC staining was performed with rabbit anti-VEGF-A
and CD34 antibodies. All primary antibodies were in-
cubated at 4 °C overnight, followed by horseradish
peroxidase-conjugated anti-rabbit secondary antibody
at room temperature for one hour. Sections were
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visualized with DAB substrate (Dako). Images were
captured at 40X and analyzed by image pro plus 6.0
software.
Positive index of VEGF-A was calculated based upon:
the sum of (density of positive area x size of area)
divided by total area. For CD34 staining, blood vessel
rich “hot-spots” were pictured and microvessel density
(MVD) were calculated by image analysis software
directly.
Statistical analysis
Quantitative data with two groups were tested by un-
paired Student’s t-test using Excel software (Microsoft,
Seattle, WA). Quantitative data of over two groups were
initially evaluated by analysis of variance followed by
Tukey test, to evaluate pairwise comparisons using Graph-
Pad Software (Abacus Concepts, Berkeley, CA). Data
transformation by square root was used to meet the nor-
mality requirement. P < 0.05 was considered as significant.
Results
TMZ and RG3 additively inhibited HUVEC proliferation in
vitro
MTS assay showed that TMZ dose and time dependently
inhibited HUVEC proliferation. At the concentration of as
low as 10 μg/ml and incubation for 24 h, TMZ sig-
nificantly inhibited HUVEC proliferation by 3.96 ±
0.23 % (P < 0.05 compared with the vehicle). As high
as 45.73 ± 1.56 % of cell proliferation was inhibited by
TMZ at the concentration of 180 μg/ml after 144 h
incubation (P < 0.0001 compared with the vehicle) (Fig. 1a).
RG3 treatment showed similar dose and time dependent
inhibition on HUVEC proliferation. RG3 significantly re-
duced HUVEC proliferation by 3.12 ± 0.66 % at the con-
centration of 10 μg/ml after 24 h treatment (P < 0.05).
There was 28.36 ± 1.49% inhibition of cell proliferation by
RG3 at 180 μg/ml for 144 h incubation (Fig. 1b).
LMZ and RG3 combined treatment showed additive in-
hibition on HUVEC proliferation. After incubation with
10 ug/ml TMZ and 10 μg/m RG3 together for 24 h,
HUVEC proliferation was reduced by 5.43 ± 0.39 %,
whereas only 3.96 ± 0.23 % (P < 0.05 compared to com-
bined) and 3.12 ± 0.66 % (P < 0.05 compared to com-
bined), respectively, of proliferation inhibition was
observed by treatment with TMZ or RG3 alone. Com-
bined treatment with TMZ 180 μg/ml and RG3 180 μg/ml
showed 52.37 ± 1.46 % inhibition of HUVEC proliferation
after 144 h incubation (Fig. 1c).
TMZ and RG3 arrested cell cycle and induced apoptosis in
HUVECs
We then determined the effect of TMZ or RG3 on cell cy-
cles of HUVECs by flow cytometry. The flow cytometry
results showed that individual TMZ or RG3 treatment
arrested HUVEC cell cycle at S phase, in a dose dependent
manner (Fig. 2a, b, c). However, longer time treatment did
not significantly increase the effect of cell cycle arrest.
Individual TMZ or RG3 treatment led to dose and
time dependent increases in apoptosis of HUVECs
(Fig. 2d, e). Combined treatment with TMZ and RG3
showed additive effects on inducing apoptosis ((Fig. 2f ).
The apoptosis rates of HUVEC treated with individual
TMZ (80 μg/ml) or RG3 (80 μg/ml) for 72 h were
18.8 ± 2.7% and 11.4 ± 1.9%, respectively. Combined
treatment with TMZ and RG3 additively increased the
apoptosis rate to 25.3 ± 3.3% (both P < 0.05 vs individ-
ual treatment). The apoptosis of HUVEC induced by
TMZ or RG3 treatment was validated by characteris-
tic DNA ladder (Fig. 2g).
TMZ and RG3 reduced VEGF-A and Bcl-2 expression in
HUVECs
Real time PCR results showed treatment with either
TMZ (80 μg/ml) or RG3 alone (80 μg/ml) for 72 h sig-
nificantly decreased both VEGF and Bcl-2 mRNA in
HUVECs (all P < 0.01 compared to control (Fig. 2h).
Combined treatment with TMZ and RG3 further de-
creased mRNA of both VEGF and Bcl-2 in HUVEC
(both P < 0.05 compared to individual treatment).
TMZ and RG3 additively suppressed rat C6 glioma
proliferation in vitro
Similar to their inhibitory effects on HUVEC, treatment
with individual TMZ and RG3 showed dose and time
dependent inhibition on rat C6 glioma cell proliferation
(Fig. 3a, b). Combined treatment with RG3 and TMZ
showed additive inhibition on C6 proliferation (Fig. 3c).
The effect of TMZ and RG3 on allografted rat glioma
growth
All rats began to decrease body weights 13 days after the
inoculation of C6 glioma cells. One rat in the control
group died 20 days after inoculation. This allograft ex-
periment was terminated on day 23 after inoculation
since three mice in the control group needed to be eu-
thanized due to sickness. Rats in control and MTD
LDM groups had the most body weight loss. Treatment
with LDM TMZ and RG3 individually or in combination
led to similar but less body weight loss (Additional file 1:
Table S1).
We then examined the inhibitory effect of treatments
on tumor growth based on the T1W+C tumor sectional
areas measured on MRI images (Fig. 4a). Our results
showed that the sectional area of tumors from control
and RG3 groups were 0.51 ± 0.11 and 0.50 ± 0.09 cm2
(P > 0.05, control vs RG3 group), respectively. The tumor
sectional areas from MTD TMZ, LDM TMZ, LDM
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TMZ and RG3 combined groups were 0.31 ± 0.17, 0.31
± 0.13 and 0.35 ± 0.15 cm2, respectively. Statistical ana-
lysis showed that all P < 0.05 compared with the control
or RG3 group, whereas no significant difference was ob-
served among the above three groups (Fig. 4b). Results
of the T2W tumor cross-sectional areas had similar
pattern to those in T1W+C (Fig. 4b). The tumor cross-
sectional areas for the control and RG3 groups are 0.65
± 0.07 and 0.59 ± 0.09 cm2, respectively (P > 0.05, control
vs RG3 group). Compared with the above two groups,
MTD TMZ, LDM TMZ alone, or LDM TMZ and RG3
combined treatment significantly decreased tumor cross
sectional areas to 0.41 ± 0.17, 0.49 ± 0.12 and 0.46 ±
0.14 cm2, respectively (all P < 0.05 compared to control or
RG3 group). There was no significant difference among
the above three groups. Linear regression model was ap-
plied to determine the correlation between T1W+C and
T2W tumor sectional areas. Our results showed a good
correlation between these two parameters of tumor cross-
sectional areas (R = 0.912, P < 0.001) (Fig. 4c).
Fig. 1 TMZ and RG3 additively inhibited HUVEC proliferation. Cells were seeded in 24 well plates and treated with TMZ and/or RG3 for
designated time and doses. a TMZ inhibited HUVEC proliferation in a time and dose dependent way. b RG3 inhibited HUVEC proliferation in a
time and dose dependent way. c TMZ and RG3 additively inhibited proliferation of HUVECs. Bars with different letters indicate significant
difference (P < 0.05) based on post-hoc Tukey analysis
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We also calculated tumor volume based on T1 en-
hancement from MRI scanning. The average tumor vol-
ume of the control and RG3 groups were 0.61 ± 0.17 and
0.53 ± 0.15 cm3, respectively (P > 0.05). In contrast,
MTD TMZ, LDM TMZ alone, LDM TMZ and RG3
combined treatment, all showed a significant decrease in
tumor volume, compared to the control or RG3 group
(all P < 0.05). The mean tumor volumes for MTD, LDM
TMZ, and combined LDM TMZ and RG3 groups were
0.29 ± 0.12, 0.19 ± 0.12, and 0.38 ± 0.15 cm3, respectively.
Fig. 2 Effect of TMZ and RGs on cell cycle and apoptosis of HUVECs. a Representative flow cytometry histograms of cell cycles. Treatment with
TMZ (80 μg/ml) or RG3 (80 μg/ml) for 72 h led to accumulation of S phase and appearance of sub-G0 apoptotic cells. b HUVEC cell cycle arrested
at S phase after treatment with TMZ. c. HUVEC cell cycle arrested at S phase after treatment with RG3. d Rates of apoptotic cells after treatment
with TMZ. e Rates of apoptotic cells after treatment with RG3. f Additive effect of TMZ and RG3 on cell apoptosis. g A representative image of
DNA ladder after treatment with TMZ (80 μg/ml) or RG3 (80 μg/ml) for 48 h. h Realtime PCR data showed that TMZ and RG3 additively reduced
both VEGF and Bcl-2 expression compared to vehicle treated control, which was set to 100 %. Bars with different letters indicate significant
difference (P < 0.05) based on post-hoc Tukey analysis
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There was no significant difference in tumor volume
among the above three groups.
Our results showed that MTD TMZ, LDM TMZ, and
combined treatments had similar effects in induction of
necrosis in allografted gliomas. They all significantly in-
creased the necrosis areas in tumors compared to the
control or RG3 treatment (Additional file 2: Table S2).
The effect of TMZ and RG3 on angiogenesis in rat glioma
The relative cerebral blood volume (rCBV) was mea-
sured by dynamic susceptibility-weighted contrast-
enhanced perfusion MRI (Fig. 5a). Based on rCBV,
tumor blood contents were quantified and compared on
the days 13 and 23 after the C6 rat glioma cell inocula-
tion. Compared with day 13, there was 90.5 ± 29.1 % in-
crease in rCBV in the control group on day 23. In
contrast, RG3 and MTD TMZ groups showed 65.4 ±
21.5 and 64.9 ± 18.7 %, respectively, increase in rCBV
(both P < 0.05 compared with the control group, no dif-
ference between the two groups). LDM TMZ alone
and combined treatment with LDM TMZ and RG3
had even less increase in rCBV. rCBV was increased
Fig. 3 TMZ and RG3 additively inhibited rat C6 glioma cell proliferation. Cells were seeded in 24 well plates and treated with TMZ and/or RG3 for
designated time and doses. a TMZ inhibited C6 glioma cell proliferation in a time and dose dependent manner. b RG3 inhibited C6 glioma cell
proliferation in a time and dose dependent way. c TMZ and RG3 additively inhibited proliferation of C6 glioma cells. Bars with different letters
indicate significant difference (P < 0.05) based on post-hoc Tukey analysis
Sun et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:32 Page 7 of 12
by 51.2 ± 18.3 % in the LDM TMZ group (P < 0.01
compared with the control group, P < 0.05 compared
to MTD or RG3 group), and by 15.4 ± 12.9 % in com-
bined treatment group (all P < 0.01 compared with the
control group, or MTD TMZ, or RG3 group, P < 0.05
compared with LDM TMZ group) (Fig. 5b).
We then measured the levels of proangiogenic factor
VEGF-A by IHC staining on harvested allografted gli-
omas. Our results showed that VEGF-A expression was
very low in the normal rat brain tissues and mainly lo-
calized at areas surrounding blood vessels (Fig. 5c upper
left panel). There were varied levels of VEGF-A expres-
sion in glioma cells and tumor endothelial cells after dif-
ferent treatments (Fig. 5c, middle and lower left panel).
Quantitative data showed that RG3 alone had a signifi-
cant reduction in VEGF expression compared to control.
Treatment with MTD TMZ, or LDM TMZ, or com-
bined treatment with LDM TMZ and RG3 further re-
duced expression of VEGF-A (all P < 0.01 compared to
the control, P < 0.05 compared to RG3 group, but no sig-
nificant difference among themselves) (Fig. 5d).
Antiangiogenic effect was further evaluated by tumor
microvessel density (MVD) using IHC staining of CD34.
Normal rat brains had a limited amount of expression in
vascular endothelial cells (Fig. 5c, upper right panel).
Different levels of CD34 staining were localized in gli-
oma vascular endothelial cells (Fig. 5c, middle and lower
right panel). Similar to its effect on VEGF-A expression,
RG3 alone significantly decreased MVD in allografted
glioma compared to the control group (P < 0.05). MTD
TMZ had had more potency than RG3 alone in reducing
MVD (P < 0.05 vs RG3 alone). Treatment with LDM
TMZ alone further significantly decreased MVD com-
pared with the RG3 alone or MTD TMZ (both P < 0.05).
Combined treatment with LDM TMZ and RG3 showed
the highest decrease in MVD (P < 0.05 compared with
all other groups) (Fig. 5e).
Discussion
In contrast to the standardized schedule, LDM TMZ has
been shown to have increased efficacy in the treatment
of glioblastoma, with less toxicity. One of the main
mechanisms of glioblastoma resistance to TMZ is
thought to be mediated by O6-methylguanine-DNA
methyltransferase (MGMT). It has been speculated that
LDM TMZ will deplete MGMT and accumulate higher
levels of O6-mehtylated DNA adducts, thus reducing
the chemotherapeutic resistance [31]. Furthermore, re-
cent data imply that antiangiogeneis is the main mech-
anism attributing to this enhanced efficacy in treatment
of glioblastoma. In vitro studies reveal that LDM TMZ
treatment significantly inhibits endothelial cell prolifera-
tion, and endothelial cells are more sensitive to TMZ than
glioblastoma cells [32, 33]. The LDM TMZ demonstrated
Fig. 4 Metronomic TMZ inhibited growth of allografted glioma in rats. a Representative T1W + C and T2W MRI images. b Section areas of tumors
based on T1W + C or T2W MRI images at day 23. c A significant correlation was observed between T1W + C and T2W section areas. d Sizes of
allografted gliomas after different treatments. Bars with different letters indicate significant difference (P < 0.05) based on post-hoc Tukey analysis
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the antiangiogenic effect in a mouse model of orthotopic
xenografted glioma [13]. Our current in vivo data show
that LDM TMZ is even more potent than the MTD on
angiogenesis inhibition in glioma. In addition, our in vitro
and in vivo data demonstrate that LDM TMZ treatment
reduces the levels of proangiogenetic factor VEGF. In con-
sistence with our result, LDM TMZ has been shown to
prolong glioblastoma patient progression-free interval and
overall survival with less toxicity in several clinical trials
[14–17]. However, LDM TMZ alone still has a limited ef-
fect on glioblastoma relapse. It is of clinical significance to
identify antiangiogenesis agents to improve its efficacy in
the treatment of glioblastoma.
RG3 is the active component of ginseng, which is a
popular herbal medicine used to proactively promote
health, vitality, and longevity. In contrast to other regu-
lar chemotherapeutic drugs, RG3 has been shown to be
relatively safe and effective, with little side effects. Its
antiangiogenesis effects have been demonstrated in mul-
tiple tumor models, along with its antitumor effects
[34–38]. In addition, chronic use of RG3 inhibits glioma
growth via Akt dependent pathway [28] and inhibits
Fig. 5 Metronomic TMZ and RG3 additively inhibited angiogenesis in allografted glioma in rats. a Representative MRI images showing rCBV of
days 13 and 23 after C6 rat glioma cell inoculation. b Changes in rCBV from day 13 to 23 after different treatments. c Representative images of
IHC staining of VEGF and CD34 in allografted gliomas. d Quantitative data of VEGF expression in tumors after different treatments. e Quantitative
data of CD34 expression in tumors after different treatments. Bars with different letters indicate significant difference (P < 0.05) based on post-hoc
Tukey analysis
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glioma cell proliferation by changing redox status [39].
Our current study shows that RG3 alone significantly in-
hibits proliferation, arrests the cell cycle and induces
apoptosis in HUVEC through reducing VEGF and Bcl-2
expression. RG3 demonstrates a modest antitumor and
antiangiogenesis effect in allografted gliomas. All these
data suggest that RG3 is an excellent candidate antian-
giogenesis drug to be used in combination therapy.
The novel finding of this study is that combined treat-
ment with LDM TMZ and RG3 additively inhibits gli-
oma cell growth in vitro, and suppresses angiogenesis
both in vitro and in vivo. It is noted that this additive
antiangiogenesis effect is observed in orthotopic allo-
grafted glioma in immune competent rats. Their additive
antiangiogenesis effect is through arresting the cell cycle,
inducing apoptosis and reducing expression of VEGF
and Bcl-2 in blood vessel endothelial cells. Though the
mechanism attributing to this additive effect is still un-
known, RG3 has been shown to increase the concentra-
tion of the chemotherapeutic drug paclitaxel in tumors
[40]. RG3 combined with gemcitabine inhibits angiogen-
esis of lung cancer and improves survival of tumor-
bearing mice [41]. Combined use of TMZ with other
drugs has shown their improved effects compared with
TMZ alone [42, 43]. Based on body weight change in gli-
oma bearing rats, combination therapy with LDM TMZ
and RG3 have less toxicity to the host than MTD TMZ.
To the best of our knowledge, this study is the first to
report the additive antiangiogenesis effect of combined
therapy with LDM TMZ and RG3 in the treatment of
gliomas.
Antiangiogenesis therapy has recently been added to
the panel of cancer therapeutics. Predictive biomarkers
are important to evaluate of efficacy of treatment. MVD
is closely related to tumor growth, metastasis and prog-
nosis. Due to tumor heterogeneity, invasive biopsy or
partial biopsy alone may not fully reflect the entire
tumor growth. In addition, biopsy has the limitations of
its use in glioblastoma particularly because of the ethical
issue to obtain tissue specimens from brain tumors.
Serological markers such as VEGF and bFGF have a
good correlation with glioblastoma blood vessel density,
but are vulnerable to a variety of metabolic factors that
may interfere in vivo. Conventional CT and MRI inspec-
tion, based on morphological changes and other indirect
signs, are difficult to assess tumor angiogenesis. CT
perfusion imaging has a good correlation with tumor
angiogenesis [44], but has radiation hazards. Dynamic
susceptibility-weighted contrast-enhanced perfusion
MRI is the most commonly used non-invasive method
to assess cerebral perfusion and tumor vascularity in the
central nervous system [30, 45–48]. Our data show that
rCBV measured by this type of MRI has a pattern simi-
lar to the angiogenesis biomarkers VEGF and MVD.
This non-penetrative measurement might be an object-
ive biomarker in the assessment of antiangiogenesis
therapies [49].
Conclusions
This study provides supporting data showing that LDM
TMZ has improved efficacy and decreased side effects.
Notably, our data provide strong preclinical evidence
that combined use of LDM TMZ and RG3 have additive
antiangiogenic effects. The combined additive effect sug-
gests that RG3 has the potential to further increase the
efficacy of LDM TMZ in the treatment of glioblastoma.
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